Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 915-922

  Koshy, Matthew ^a,b   Fedewa, Stacey A ^c   Malik, Renu ^b   Ferguson, Mark K ^b,d   Vigneswaran, Wickii T ^b   Feldman, Lawrence ^b   Howard, Andrew ^a,b   Abdelhady, Khaled ^d   Weichselbaum, Ralph R ^a,b   Virgo, Katherine S ^c,e  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Lung cancer; Neoadjuvant chemoradiation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE;

EID: 84880923620     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828f68b4     Document Type: Article

References (36)

1. Rigas JR, Kelly K. Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2007;2 Suppl 2:S77-S85.
2. Anderson CS, Curran WJ. Combined modality therapy for stage III nonsmall- cell lung cancer. Semin Radiat Oncol 2010;20:186-191.
3. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880-1892.
4. Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twicedaily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997;15:712-722.
5. Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997;17:147-161.
6. Burkes RL, Shepherd FA, Blackstein ME, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 2005;47:103-109.
7. Edelman MJ, Suntharalingam M, Burrows W, et al. Phase I/II trial of hyperfractionated radiation and chemotherapy followed by surgery in stage III lung cancer. Ann Thorac Surg 2008;86:903-910.
8. Friedel G, Budach W, Dippon J, et al. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 2010;28:942-948.
9. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
10. van Meerbeeck JP, Kramer GW, Van Schil PE, et al.; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450.
11. Thomas M, Rübe C, Hoffknecht P, et al.; German Lung Cancer Cooperative Group. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008;9:636-648.
12. De Craene S, Surmont V, van Meerbeeck JP. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. Curr Opin Oncol 2010;22:102-111.
13. Commission on Cancer. Facility Oncology Registry Data Standards (FORDS) Revised for 2007. Chicago, IL: American College of Surgeons, 2007.
14. Robinson LA, Ruckdeschel JC, Wagner H Jr, Stevens CW; American College of Chest Physicians. Treatment of non-small cell lung cancerstage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 Suppl):243S-265S.
15. Pfister DG, Johnson DH, Azzoli CG, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
16. Pisters KM, Evans WK, Azzoli CG, et al.; Cancer Care Ontario; American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007;25:5506-5518.
17. D'Addario G, Felip E; ESMO Guidelines Working Group. Non-smallcell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:68-70.
18. Ettinger DS, Akerley W, Bepler G, et al.; NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
19. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual, 6th Ed. New York: Springer-Verlag, 2002.
20. Groome PA, Bolejack V, Crowley JJ, et al.; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705.
21. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P; International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008;3:457-466.
22. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
23. Clark TG, Bradburn MJ, Love SB, Altman DG. Survival analysis part I: basic concepts and first analyses. Br J Cancer 2003;89:232-238.
24. Kleinbaum DG, Klein M. Survival analysis. 2012: 700. Available at: http://encompass.library.cornell.edu/cgi-bin/checkIP.cgi?access= gateway-standard%26url=http://dx.doi.org/10.1007/978-1-4419-6646-9. Accessed October 2, 2012.
25. Ata NSM. Cox regression models with nonproportional hazards applied to lung cancer survival data. Hacc J Math Stat 2007;38: 157.
26. Park HS, Gross CP, Makarov DV, Yu JB. Immortal time bias: A frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2012.
27. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-719.
28. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-499.
29. Depierre A, Milleron B, Moro-Sibilot D, et al.; French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20: 247-253.
30. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45: 2744-2753.
31. Kunitoh H, Suzuki K. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer. Br J Cancer 2007;96:1498-1503.
32. Roy MS, Donington JS. Management of locally advanced non small cell lung cancer from a surgical perspective. Curr Treat Options Oncol 2007;8:1-14.
33. Koshy M, Goloubeva O, Suntharalingam M. Impact of neoadjuvant radiation on survival in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1388-1394.
34. Wang J, Kuo YF, Freeman J, Markowitz AB, Goodwin JS. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer 2008;112:382-390.
35. Nuttall M, van der Meulen J, Emberton M. Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol 2006;59:265-273.
36. West H, Albain KS. Current standards and ongoing controversies in the management of locally advanced non-small cell lung cancer. Semin Oncol 2005;32:284-292.